HK1146284A1 - Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation 23-26- fsh - Google Patents

Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation 23-26- fsh

Info

Publication number
HK1146284A1
HK1146284A1 HK11100441.2A HK11100441A HK1146284A1 HK 1146284 A1 HK1146284 A1 HK 1146284A1 HK 11100441 A HK11100441 A HK 11100441A HK 1146284 A1 HK1146284 A1 HK 1146284A1
Authority
HK
Hong Kong
Prior art keywords
alpha
fsh
sialylation
recombinant
including alpha
Prior art date
Application number
HK11100441.2A
Other languages
English (en)
Chinese (zh)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1146284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Publication of HK1146284A1 publication Critical patent/HK1146284A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK11100441.2A 2008-04-16 2011-01-17 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation 23-26- fsh HK1146284A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (fr) 2008-04-16 2009-04-16 Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6

Publications (1)

Publication Number Publication Date
HK1146284A1 true HK1146284A1 (en) 2011-05-20

Family

ID=39717519

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11100441.2A HK1146284A1 (en) 2008-04-16 2011-01-17 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation 23-26- fsh
HK14112411.0A HK1199039A1 (en) 2008-04-16 2014-12-10 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation 23-26- fsh

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14112411.0A HK1199039A1 (en) 2008-04-16 2014-12-10 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation 23-26- fsh

Country Status (29)

Country Link
US (5) US8951967B2 (fr)
EP (7) EP2808340B1 (fr)
JP (7) JP2011519359A (fr)
KR (5) KR20160056960A (fr)
CN (3) CN102066414A (fr)
AR (1) AR071479A1 (fr)
AU (5) AU2009237479B2 (fr)
BR (1) BRPI0910461B8 (fr)
CA (1) CA2725257A1 (fr)
CY (1) CY1115413T1 (fr)
DK (4) DK3045471T3 (fr)
ES (3) ES2468318T3 (fr)
FR (1) FR17C1020I2 (fr)
HK (2) HK1146284A1 (fr)
HR (3) HRP20140535T1 (fr)
HU (5) HUE030652T4 (fr)
IL (2) IL208538A (fr)
LT (4) LT2808340T (fr)
MX (3) MX355457B (fr)
NO (2) NO2017025I1 (fr)
NZ (1) NZ588381A (fr)
PL (4) PL2268666T3 (fr)
PT (4) PT2808340T (fr)
RU (3) RU2682270C2 (fr)
SA (1) SA109300228B1 (fr)
SI (4) SI2268666T1 (fr)
TW (1) TWI488640B (fr)
WO (1) WO2009127826A1 (fr)
ZA (1) ZA201007373B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (fr) 2010-07-30 2012-02-15 Ferring B.V. Stabilisation de gonadotrophines
WO2012016576A1 (fr) * 2010-08-04 2012-02-09 Glycotope Gmbh Hormone folliculostimulante humaine recombinante améliorée
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
WO2012050175A1 (fr) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 Procédé de production de glycoprotéines ayant un résidu mannose comme extrémité non réductrice de la chaîne sucrée
CA3163525A1 (fr) * 2011-03-31 2012-10-04 Ferring Bv. Preparation pharmaceutique
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (fr) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, procédés et trousses pour la préparation de protéines recombinantes sialylées
EP2848687B1 (fr) * 2012-04-27 2017-09-13 JCR Pharmaceuticals Co., Ltd. Nouveau vecteur d'expression
EP2824176A1 (fr) * 2013-07-11 2015-01-14 Siamed'xpress Procédés de production de protéines thérapeutiques sialylées
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3237608B1 (fr) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Activité de la sialidase dépendante du cmp
SI3662925T1 (sl) 2015-04-17 2021-08-31 Ferring B.V. Sestavek, ki vsebuje FSH za zdravljenje neplodnosti
KR20180020982A (ko) * 2015-06-26 2018-02-28 훼링 비.브이. 정제 방법 및/또는 바이러스 불활화 처리 방법
EP3205719A1 (fr) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Lignées cellulaires pour la production de glycoprotéines recombinées avec des n-glycanes di-antennulaire, procédés d'utilisation de ces derniers et des glycoprotéines de recombinaison
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (fr) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Glycoprotéines recombinées avec une fucosylation antennulaire réduite
IL272763B2 (en) 2017-09-01 2024-02-01 Ferring Bv The composition for controlled stimulation of the ovary
JP2021522268A (ja) 2018-04-30 2021-08-30 フェリング ベスローテン フェンノートシャップ 制御された卵巣刺激のための組成物
CA3110205A1 (fr) 2018-10-17 2020-04-23 Ferring Bv Compositions et methodes de stimulation ovarienne controlee
WO2021081670A1 (fr) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions et procédés pour l'o-glycosylation de type mucine sialylée de protéines thérapeutiques
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
WO2023186331A1 (fr) 2022-04-01 2023-10-05 Ferring B.V. Protocole mixte pour le traitement de l'infertilité
WO2023227761A1 (fr) 2022-05-26 2023-11-30 Ferring B.V. Compositions et méthodes de traitement de l'infertilité chez les hommes
WO2024008971A1 (fr) 2022-07-08 2024-01-11 Ferring B.V. Compositions et procédés d'insémination intra-utérine (iiu)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
ATE263841T1 (de) 1997-01-16 2004-04-15 Neose Technologies Inc Praktische in vitro sialylierung von rekombinanten glykpproteinen
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
US7304031B2 (en) 2001-10-29 2007-12-04 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
ATE332705T1 (de) 1999-05-07 2006-08-15 Applied Research Systems Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
MEP38608A (en) * 2001-10-22 2011-02-10 Merck Serono Sa Gonadotrophins for folliculogenesis
ES2297028T3 (es) 2001-12-07 2008-05-01 Crucell Holland B.V. Produccion de virus, aislados virales y vacunas.
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (fr) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Hormone stimulant le follicule humain glycopegyle
US8431355B2 (en) 2004-02-04 2013-04-30 Universite De Provence Aix-Marseille 1 Process for screening glycoform-specific antibodies
US8609370B2 (en) * 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (fr) 2010-07-30 2012-02-15 Ferring B.V. Stabilisation de gonadotrophines
EP2600809B1 (fr) 2010-08-03 2015-02-25 King Saud University Ensemble pour stomie
WO2012016576A1 (fr) 2010-08-04 2012-02-09 Glycotope Gmbh Hormone folliculostimulante humaine recombinante améliorée
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CA3163525A1 (fr) 2011-03-31 2012-10-04 Ferring Bv. Preparation pharmaceutique
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
SG11201608132UA (en) 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
US9546204B2 (en) 2017-01-17
EP2808340A1 (fr) 2014-12-03
AU2017204258A1 (en) 2017-07-20
CA2725257A1 (fr) 2009-10-22
DK2808340T3 (en) 2016-12-05
RU2014141994A (ru) 2016-05-10
NO2017025I1 (no) 2017-06-06
LT3045471T (lt) 2017-07-10
AU2017225020A1 (en) 2017-09-28
LTPA2017029I1 (lt) 2017-10-10
ES2610277T3 (es) 2017-04-26
HUE030652T4 (en) 2017-09-28
US9771407B2 (en) 2017-09-26
SI3045471T1 (sl) 2017-07-31
IL230571A (en) 2015-11-30
MX355457B (es) 2018-04-19
AU2017204258B2 (en) 2017-08-17
HRP20161520T1 (hr) 2016-12-30
HRP20170958T1 (hr) 2017-09-22
JP6486310B2 (ja) 2019-03-20
LTPA2017018I1 (lt) 2017-06-26
NO2017050I1 (no) 2017-09-28
SA109300228B1 (ar) 2014-04-08
EP2722339A1 (fr) 2014-04-23
MX2010011343A (es) 2011-01-20
PT2808340T (pt) 2016-11-21
TWI488640B (zh) 2015-06-21
KR20170110741A (ko) 2017-10-11
JP2018021037A (ja) 2018-02-08
EP2268666B1 (fr) 2014-03-12
AU2017204259B2 (en) 2017-08-17
FR17C1020I2 (fr) 2020-04-10
CN105906702A (zh) 2016-08-31
PL3144318T3 (pl) 2021-02-08
EP3045471A1 (fr) 2016-07-20
ES2468318T3 (es) 2014-06-16
AU2017225020B2 (en) 2019-11-14
PT2268666E (pt) 2014-06-25
US10995128B2 (en) 2021-05-04
HUS1700024I1 (hu) 2017-06-28
US20110105398A1 (en) 2011-05-05
RU2682270C2 (ru) 2019-03-18
DK3045471T3 (en) 2017-06-26
US11952407B2 (en) 2024-04-09
IL208538A (en) 2014-03-31
AU2017204259A1 (en) 2017-07-20
KR20160056960A (ko) 2016-05-20
SI2268666T1 (sl) 2014-07-31
IL208538A0 (en) 2010-12-30
DK3144318T3 (da) 2020-12-07
PT3144318T (pt) 2020-11-04
AR071479A1 (es) 2010-06-23
MX348622B (es) 2017-06-22
NZ588381A (en) 2012-05-25
US20180079794A1 (en) 2018-03-22
US20210332099A1 (en) 2021-10-28
PL2268666T3 (pl) 2014-08-29
LT2808340T (lt) 2016-11-10
RU2745557C1 (ru) 2021-03-29
JP2011519359A (ja) 2011-07-07
AU2009237479A1 (en) 2009-10-22
DK2268666T3 (da) 2014-05-12
TW200948378A (en) 2009-12-01
KR101622944B1 (ko) 2016-05-23
PL3045471T3 (pl) 2017-10-31
SI3144318T1 (sl) 2020-12-31
JP2020040956A (ja) 2020-03-19
EP3045471B1 (fr) 2017-03-29
KR20190092608A (ko) 2019-08-07
HUS1700025I1 (hu) 2017-06-28
FR17C1020I1 (fr) 2020-04-10
HUE033830T2 (en) 2018-01-29
CN102066414A (zh) 2011-05-18
KR102108377B1 (ko) 2020-05-08
EP3098234A1 (fr) 2016-11-30
PL2808340T3 (pl) 2017-02-28
EP4015527A1 (fr) 2022-06-22
WO2009127826A1 (fr) 2009-10-22
BRPI0910461B1 (pt) 2021-02-23
RU2745557C3 (ru) 2021-12-10
PT3045471T (pt) 2017-06-14
CY1115413T1 (el) 2017-01-04
BRPI0910461A8 (pt) 2018-10-16
AU2014203277A1 (en) 2014-07-24
EP2268666A1 (fr) 2011-01-05
EP2808340B1 (fr) 2016-08-17
JP7316905B2 (ja) 2023-07-28
AU2014203277C1 (en) 2017-07-27
JP2022031652A (ja) 2022-02-22
US20150065695A1 (en) 2015-03-05
JP2017060476A (ja) 2017-03-30
AU2009237479B2 (en) 2014-05-15
BRPI0910461A2 (pt) 2018-03-27
BRPI0910461B8 (pt) 2021-05-25
RU2537268C2 (ru) 2014-12-27
ZA201007373B (en) 2011-06-29
US8951967B2 (en) 2015-02-10
JP2024038000A (ja) 2024-03-19
AU2014203277B2 (en) 2017-04-06
HUE030652T2 (en) 2017-05-29
EP3144318B1 (fr) 2020-09-23
RU2014141994A3 (fr) 2018-05-28
US20160347811A1 (en) 2016-12-01
KR20110005863A (ko) 2011-01-19
EP3098234B1 (fr) 2024-07-31
CN105906703A (zh) 2016-08-31
HRP20140535T1 (hr) 2014-07-18
HK1199039A1 (en) 2015-06-19
ES2629392T3 (es) 2017-08-09
HUS1700036I1 (hu) 2017-10-30
EP3144318A1 (fr) 2017-03-22
JP6762916B2 (ja) 2020-09-30
RU2010141908A (ru) 2012-05-27
JP2015120696A (ja) 2015-07-02
SI2808340T1 (sl) 2016-12-30
KR20180095140A (ko) 2018-08-24

Similar Documents

Publication Publication Date Title
HUS1700036I1 (hu) Rekombináns, alfa-2,3- és alfa-2,6-szializációt tartalmazó FSH
EP2344648A4 (fr) Vecteurs recombinants
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
AP2010005388A0 (en) Pupicidal and larvicidal composition.
ZA201005346B (en) 3,8-diaminotetrahydroquinoline derivative
IL207174A0 (en) Peptides, compositions, and uses thereof
LT3144318T (lt) Rekombinantinis fsh, įskaitant alfa-2,3- ir alfa-2,6-sialilinimą
GB0715213D0 (en) Igf-1
EP2384338A4 (fr) Analogues de glp-1 et leurs applications
GB0808401D0 (en) Fsh
GB0813815D0 (en) Corcost Pre 1001,10
GB0809709D0 (en) Dunhill car,2093
GB0705503D0 (en) The buffer
GB0808811D0 (en) Algabe 2.1
GB0717996D0 (en) Composites
GB0808847D0 (en) 10000001
GB0808958D0 (en) 10000004
GB0808845D0 (en) 10000003
GB0808846D0 (en) 10000002